A new antiviral drug that induces mutations in the genetic material of influenza virus is highly effective in treating influenza infection in animals and human airway tissue and could be a groundbreaking advance in influenza therapy, according to a study by the Institute for Biomedical Sciences at Georgia State University.
The antiviral drug blocks RNA polymerase, the enzyme that plays a central role in replicating the genome of influenza virus, causing mutations in the viral genome. If enough mutations occur, the genome becomes nonfunctional and the virus cannot replicate. The findings were published online on Oct. 23 in Science Translational Medicine.
“The compound is highly efficacious against influenza,” said Dr. Richard Plemper, senior author of the study and a professor in the Institute for Biomedical Sciences. “It’s orally available, it’s broad spectrum against all influenza virus strains tested, and most important it establishes a high barrier against viral escape from inhibition.”
Influenza, caused by a contagious respiratory virus, is characterized by fever, cough, headache, muscle and joint pain, severe malaise, sore throat and sometimes gastrointestinal symptoms. Patients in higher risk groups, such as older adults and individuals with compromised immune systems, frequently require hospitalization. Each year, seasonal influenza results in 30,000 to 80,000 fatalities in the United States. The seasonal flu vaccine is only moderately effective, and licensed antivirals are compromised by rapidly emerging viral resistance to the drugs.
In the study, the new antiviral drug was tested in ferrets, the most informative animal model for human influenza disease, against various strains that include seasonal and pandemic viruses, such as the swine-origin influenza virus responsible for a 2009 pandemic. The researchers found that the antiviral drug efficiently inhibited replication of all of these strains. Virus burden dropped rapidly after treatment, and the duration of fever was significantly shorter in treated ferrets than in control animals that did not receive the drug.
“We think that the next generation of influenza antiviral drugs must not only be efficacious and safe, but also address the resistance problem,” said Dr. Mart Toots, first author of the study and a research assistant professor associated with Dr. Plemper’s lab in the Institute for Biomedical Sciences.
That is where the new drug comes in. Through a combination of conventional and ultra-deep sequencing, Toots has demonstrated in collaboration with Dr. Alex Greninger at the University of Washington that it is very challenging for the virus to find a viable way to avoid the compound.
“We have not identified specific resistance mutations yet and are confident to say that the genetic barrier against viral resistance is high,” Plemper said. “We believe that this compound has high clinical potential as a next-generation influenza drug that combines key antiviral features.”
The Latest on: Influenza
via Google News
The Latest on: Influenza
- IFI16 directly senses viral RNA and enhances RIG-I transcription and activation to restrict influenza virus infectionon May 13, 2021 at 2:27 pm
IFI16 enhances the type I IFN response to inhibit influenza virus replication by two mechanisms: it directly binds viral RNA to promote RIG-I activation and upregulates RIG-I expression via recruiting ...
- Influenza Therapeutics Market Covering Prime Factors and Competitive Outlook till 2027 |Top Countries data with COVID 19 Analysis| Top Key Playerson May 13, 2021 at 12:00 am
The worldwide “Influenza Therapeutics Market” research report is involved a detailed investigation of the market and ...
- Influenza Diagnostics Market Size, Share, Future Scope, Demands and Projected Industry Growths to 2025on May 12, 2021 at 9:51 pm
Influenza Diagnostics Market by Test Type (Traditional Diagnostic Test and Molecular Diagnostic Test), by End-user (Hospital, Clinical Laboratories, and Other End-Users), Geography (North America, ...
- COVID-19 is not influenza, but it offers lessons on beating it, say researcherson May 12, 2021 at 1:33 pm
If you did not catch the flu this year—and there is an overwhelming chance that you did not—you have COVID-19 to thank.
- COVID-19 is not influenza, but it offers lessons on beating it, say Concordia researcherson May 11, 2021 at 9:00 pm
Two Concordia researchers and their colleagues study the 2020 influenza figures from Canada, the United States, Australia and Brazil and show there is a clear relationship between COVID-mitigation ...
- Combo tests could detect both COVID-19 and influenza when flu re-emergeson May 11, 2021 at 11:52 am
Numerous companies have developed combination tests that simultaneously look for influenza and COVID-19, which could be especially useful as the flu potentially makes a return this fall, The New York ...
- Immune cellular networks underlying recovery from influenza virus infection in acute hospitalized patientson May 11, 2021 at 9:48 am
The immunological parameters that define severe influenza disease are not clear within human real time infections. Here the authors compare a severe influenza infection cohort with an influenza ...
- Experts predicting more influenza cases this seasonon May 11, 2021 at 9:19 am
Wearing a mask, social distancing, and quarantining kept flu transmission down last winter, but some public health experts believe we could see even more cases than ...
- How to predict severe influenza in hospitalized patientson May 11, 2021 at 8:39 am
Published today in Nature Communications, the team from the Peter Doherty Institute for Infection and Immunity (Doherty Institute), Alfred Health and Monash University sought to understand which ...
- Influenza Diagnostic Market Evolving Opportunities with Innovative Ideas by Key Players –Quidel, Analytik Jena.on May 10, 2021 at 9:47 am
The Influenza Diagnostic Market is expected to grow at a CAGR of 6.82% and is poised to reach US$XX Billion by 2027 as compared to US$XX Billion in 2020. The factors leading to this extraordinary ...
via Bing News